Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 301–400 of 2,162
Will advances in fish immunology change vaccination strategies?
Secombes, C. J. (2008) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2008.05.001 · Cited by 94
Targeting Treg signaling for the treatment of autoimmune diseases
Spence, A., Klementowicz, J. E., Bluestone, J. A., & Tang, Q. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.09.002 · Cited by 92
“When evaluated in a phase 1 clinical trial, TGN1412, the humanized agonist anti-CD28 induced pan T cell activation and severe cytokine storm in healthy volunteers [68].”
BackgroundMicrodosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development
Burt, T., Yoshida, K. J., Lappin, G., Vuong, L. T., John, C. S., de Wildt, S. N., Sugiyama, Y., & Rowland, M. (2016) · Clinical and Translational Science · doi:10.1111/cts.12390 · Cited by 101
Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway
Adams, A. B., Ford, M. L., & Larsen, C. P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601135 · Cited by 95
CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes
Steines, B., Dickey, D. D., Bergen, J., Excoffon, K. J. D. A., Weinstein, J. R., Li, X., Yan, Z., Alaiwa, M. H. A., Shah, V. S., Bouzek, D. C., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88728 · Cited by 92
“However, when tested in humans, the anti-CD28 antibody reacted with Tregs and produced adverse events (53).”
BackgroundIntracellular antibody signalling is regulated by phosphorylation of the Fc receptor TRIM21
Dickson, C., Fletcher, A. J., Vaysburd, M., Yang, J.-C., Mallery, D. L., Zeng, J., Johnson, C. M., McLaughlin, S. H., Skehel, M., Maslen, S., et al. (2018) · eLife · doi:10.7554/elife.32660 · Cited by 93
“However, the consequences of inappropriate antibody-induced inflammation are severe, including lethal cytokine storms, autoimmunity and chronic inflammatory disease (Suntharalingam et al., 2006).”
BackgroundThe Microbiota-Gut-Brain Axis in Health and Disease and Its Implications for Translational Research
Schächtle, M., & Rosshart, S. P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.698172 · Cited by 105
“…data could not be directly translated from bench to bedside practice (Fisher et al., 1996; Mestas and Hughes, 2004; von Herrath and Nepom, 2005; Suntharalingam et al., 2006; Payne and Crooks, 2007; Seok et al., 2013; Shay et al., 2013; Garner, 2014; Hay et al., 2014; Mak et al., 2014; Wong et…”
BackgroundInfluentialImmunological substance testing on human lymphatic micro-organoids in vitro
Giese, C., Lubitz, A., Demmler, C. D., Reuschel, J., Bergner, K., & Marx, U. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.03.001 · Cited by 95
Severe childhood asthma: a common international approach?
Bush, A., Hedlin, G., Carlsen, K. C. L., Benedictis, F. M. D., Lødrup-Carlsen, K. C., & Wilson, N. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61422-1 · Cited by 99
Antigen-specific induced Foxp3 + regulatory T cells are generated following CD40/CD154 blockade
Ferrer, I. R., Wagener, M. E., Song, M., Kirk, A. D., Larsen, C. P., & Ford, M. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105500108 · Cited by 93
“Alternatively, non–cross-linking mAbs could be developed to antagonize CD154, much like nonactivating single-chain FV-based reagents have been developed in lieu of cross-linking anti-CD28 mAbs (43), which has resulted in a much more severe side effect profile than that seen in anti-CD154 mAbs in pilot studies in human…”
In vitro models of cancer stem cells and clinical applications
Franco, S. S., Szczęsna, K., Iliou, M. S., Al-Qahtani, M. H., Mobasheri, A., Kobolák, J., & Dinnyés, A. (2016) · BMC Cancer · doi:10.1186/s12885-016-2774-3 · Cited by 100
“TGN1412 CD28 agonist Clinical trial phase I [267]; [307]”
BackgroundAnimal models of human disease: Inflammation
Webb, D. R. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.014 · Cited by 106
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date
Zhao, Q. (2020) · BioDrugs · doi:10.1007/s40259-019-00400-2 · Cited by 92
Regulation of advanced therapy medicinal products in Europe and the role of academia
Pearce, K. F., Hildebrandt, M., Greinix, H., Scheding, S., Koehl, U., Worel, N., Apperley, J. F., Edinger, M., Hauser, A., Weissinger, E. M., et al. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.08.003 · Cited by 94
“There is a significant risk of underestimating toxicity of human-specific biologic reagents when evaluated in animal models, even primates, because pharmacologic activity and unanticipated adverse side effects may be speciesspecific (9).”
BackgroundFcγ receptors and immunomodulatory antibodies in cancer
Gálvez‐Cancino, F., Simpson, A. P., Costoya, C., Matos, I. G., Qian, D., Peggs, K. S., Litchfield, K., & Quezada, S. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00637-8 · Cited by 104
“Importantly, the administration of theralizumab to healthy volunteers in phase I clinical trials resulted in a cytokine release syndrome (CRS) that led to severe inflammatory reactions and chronic organ failure 179 .”
Poirier, N., Dilek, N., Mary, C., Ville, S., Coulon, F., Branchereau, J., Tillou, X., Charpy, V., Pengam, S., Nerrière‐Daguin, V., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12964 · Cited by 91
“However, selective CD28 antagonists have not yet been evaluated in the clinic due to the difficulty of assessing the innocuity of antagonist anti-CD28 mAbs, in relationship with the deleterious effects of superagonists anti-CD28 mAbs in humans (44).”
BackgroundTherapeutic Antibodies Against Cancer
Adler, M. J., & Dimitrov, D. S. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.013 · Cited by 103
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
Waldron-Lynch, F., & Herold, K. C. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3402 · Cited by 106
“An extreme example of this failure is the Phase I clinical trial of the CD28 superagonist TGN1412, whereby all six healthy volunteers developed a severe cytokine release syndrome despite evidence in murine models that this did not occur at the dosage given to the volunteer”
BackgroundCorrenti, C., Laszlo, G. S., de van der Schueren, W., Godwin, C. D., Bandaranayake, A. D., Busch, M. A., Gudgeon, C. J., Bates, O. M., Olson, J. M., Mehlin, C., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0014-3 · Cited by 89
“Briefly (see Online Supplement for detailed methods), we used variable domain sequences available from the literature (Supplementary Table 1) for CD19 (blinatumomab), ROR1 (clone R12), CD3 (blinatumomab), CD28 (TGN1412), and PD-L1 (atezolizumab) to build molecules in the canonical BiTE format (Supplementary Fig.”
InfluentialZhang, T., Fresnay, S., Welty, E. E., Sangrampurkar, N., Rybak, E., Zhou, H., Cheng, X., Feng, Q., Avon, C., Laaris, A., et al. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03624.x · Cited by 92
“In vivo cytokine secretion in response to a 28scFv A fully humanized CD28 superagonist monoclonal antibody TGN1412 induced an unexpected cytokine release syndrome during a pilot human trial in 2006 (43).”
BackgroundLoisel, S., Ohresser, M. C. P., Pallardy, M. J., Daydé, D., Berthou, C., Cartron, G., & Watier, H. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.11.010 · Cited by 98
From cancer immunosurveillance to cancer immunotherapy
Stagg, J., Johnstone, R. W., & Smyth, M. J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00566.x · Cited by 107
“However, the therapeutic use of CD28 agonists in humans is severely compromised by the induction of potentially lethal toxicities (132).”
BackgroundMicrofluidic high-throughput 3D cell culture
Ko, J., Park, D., Lee, J., Jung, S., Baek, K., Sung, K. E., Lee, J., & Jeon, N. L. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00163-8 · Cited by 88
“Personalized 3D cell culture and clinical trials-on-chips Microfluidic 3D cell culture devices may serve as tools for clinical trials, particularly for rare diseases, for which treatments are challenging to study in clinical trials and for which animal models remain limited 2,210 .”
When binding is enough: nonactivating antibody formats
Labrijn, A. F., Aalberse, R. C., & Schuurman, J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.010 · Cited by 90
Bispecific antibodies engage T cells for antitumor immunotherapy
Choi, B. D., Cai, M., Bigner, D. D., Mehta, A. I., Kuan, C.-T., & Sampson, J. H. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.572874 · Cited by 91
“Indeed, potentially devastating effects associated with nonspecific lymphocyte activation have been clearly illustrated in the early discontinuation of a clinical trial studying TGN1412, a humanized anti-CD28 superantagonistic monoclonal antibody uniquely designed to activate T cells without the need for concomitant T…”
BackgroundImmTACs for targeted cancer therapy: Why, what, how, and which
Oates, J., Hassan, N. J., & Jakobsen, B. K. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.024 · Cited by 100
Horvath, C. J., & Milton, M. N. (2009) · Toxicologic Pathology · doi:10.1177/0192623309332986 · Cited by 87
“In an excellent review, Tabrizi and Roskos point out that appropriate preclinical safety testing of mAbs is usually highly predictive of human clinical PK, PD, and safety (Tabrizi and Roskos 2007).”
BackgroundLi, X., Shao, M., Zeng, X., Qian, P., & Huang, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00764-4 · Cited by 100
Biology and clinical application of CAR T cells for B cell malignancies
Davila, M. L., & Sadelain, M. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2039-6 · Cited by 100
“It is noteworthy that similar neurotoxicity has been described in patients treated with bi-specific T cell engagers or antiCD28 antibodies [51, 52].”
BackgroundCytokine storm induced by SARS-CoV-2 infection: The spectrum of its neurological manifestations
Thepmankorn, P., Bach, J. R., Lasfar, A., Zhao, X., Souayah, S., Chong, Z. Z., & Souayah, N. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155404 · Cited by 93
“TGN1412, an anti-CD28 monoclonal antibody that directly stimulates T cells triggered a systemic inflammatory response involving headache, myalgias, erythema, vasodilation, and hypotension [34].”
BackgroundInfluentialPandey, P. R., Young, K. H., Kumar, D., & Jain, N. K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01528-6 · Cited by 94
Adverse Reactions to Biologic Therapy
Patel, S. V., & Khan, D. A. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.01.012 · Cited by 89
The role of regulatory T cells in nervous system pathologies
Duffy, S. S., Keating, B. A., Perera, C. J., & Moalem‐Taylor, G. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24073 · Cited by 97
“Unfortunately, questions relating to the safety of the CD28 superagonist in humans have arisen due to a life-threatening cytokine-release syndrome reported in a phase I clinical trial in healthy volunteers (Suntharalingam et al., 2006).”
BackgroundThe Immunogenicity of Biologic Therapies
Garcês, S., & Demengeot, J. (2017) · Current problems in dermatology · doi:10.1159/000478077 · Cited by 94
The Structure of Clinical Translation: Efficiency, Information, and Ethics
Kimmelman, J., & London, A. J. (2015) · Hastings Center Report · doi:10.1002/hast.433 · Cited by 85
Haematological malignancies: at the forefront of immunotherapeutic innovation
Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85
Costimulatory pathways in transplantation
Pilat, N., Sayegh, M. H., & Wekerle, T. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.04.002 · Cited by 94
“Six healthy volunteers experienced a massive cytokine storm upon administration of a superagonistic anti-CD28 mAb [61].”
BackgroundJustification for species selection for pharmaceutical toxicity studies
Prior, H., Haworth, R., Labram, B., Roberts, R., Wolfreys, A., & Sewell, F. (2021) · Toxicology Research · doi:10.1093/toxres/tfaa081 · Cited by 85
“downstream signalling between humans and NHPs, which ultimately led to extensive, life-threatening toxicities in the first patients dosed [35] due to a severe Cytokine Release Syndrome (Cytokine storm).”
BackgroundLiu, L., Chen, J., Bae, J., Li, H., Sun, Z., Moore, C., Hsu, E. J., Han, C., Qiao, J., & Fu, Y. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00800-2 · Cited by 93
Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment
Fransen, M. F., Arens, R., & Melief, C. J. M. (2012) · International Journal of Cancer · doi:10.1002/ijc.27755 · Cited by 89
Do-Umehara, H. C., Chen, C., Urich, D., Zhou, L., Qiu, J., Jang, S., Zander, A. D., Baker, M. A., Eilers, M., Sporn, P. H. S., et al. (2013) · Nature Immunology · doi:10.1038/ni.2566 · Cited by 97
RetractedEx vivo expansion of CD4+CD25+ T regulatory cells for immunosuppressive therapy
Trzonkowski, P., Szaryńska, M., Myśliwska, J. M., & Myśliwski, A. (2008) · Cytometry Part A · doi:10.1002/cyto.a.20659 · Cited by 94
Géraud, A., Hueso, T., Laparra, A., Bigé, N., Ouali, K., Cauquil, C. A., Stoclin, A., Danlos, F., Hollebecque, A., Ribrag, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114075 · Cited by 98
Harper, J., Adams, K. J., Bossi, G., Wright, D. E., Stacey, A. R., Bedke, N., Martinez-Hague, R., Blat, D., Humbert, L., Buchanan, H., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0205491 · Cited by 84
Miller, F. G., & Joffe, S. (2009) · Journal of Medical Ethics · doi:10.1136/jme.2008.026062 · Cited by 97
Vijayakumar, G., McCroskery, S., & Palese, P. (2019) · Journal of Virology · doi:10.1128/jvi.01677-19 · Cited by 85
“In addition to anti-CD28 agonistic antibodies (18), checkpoint inhibitors induce severe immune-related adverse events with CTLA4 and PD1 pathway blockade, which have been estimated to be as high as 55% with dualcheckpoint inhibitor therapy (34).”
BackgroundBradbury, P. A., & Shepherd, F. A. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174e9a7 · Cited by 83
Materials design at the interface of nanoparticles and innate immunity
Szeto, G. L., & Lavik, E. (2016) · Journal of Materials Chemistry B · doi:10.1039/c5tb01825k · Cited by 87
Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist
Khan, D. A. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.05.013 · Cited by 91
Redeker, A., & Arens, R. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00345 · Cited by 80
“However, in order to be able to optimize ACT protocols further and minimize the chance of severe adverse side effects as observed in the Phase I clinical trial with anti-CD28 and to a lesser extent in the Phase II study with the anti-4-1BB antibody Urelumab (NCT00612664), which was associated with a high incidence of…”
BackgroundCostimulation Blockade: Current Perspectives and Implications for Therapy
Kinnear, G., Jones, N. D., & Wood, K. J. (2012) · Transplantation · doi:10.1097/tp.0b013e31826d4672 · Cited by 93
Bispecific antibody platforms for cancer immunotherapy
Lameris, R., de Bruin, R. C. G., Schneiders, F. L., Henegouwen, P. M. P. V. B. E., Verheul, H. M. W., de Gruijl, T. D., & van der Vliet, H. J. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.08.003 · Cited by 91
“[81] Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A,”
BackgroundHave we overestimated the benefit of human(ized) antibodies?
Getts, D. R., Getts, M. T., McCarthy, D. P., Chastain, E. M. L., & Miller, S. D. (2010) · mAbs · doi:10.4161/mabs.2.6.13601 · Cited by 98
Bühler, P., Wolf, P., Gierschner, D., Schaber, I., Katzenwadel, A., Schultze-Seemann, W., Wetterauer, U., Tacke, M., Swamy, M., Schamel, W. W. A., et al. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0348-6 · Cited by 82
“However, since the CD19 £ CD3 diabody could be safely applied to chimpanzees [26], and also used in a Wrst clinical trial [12], no severe side eVects like a cytokine storm in the Phase I trial of the anti-CD28 monoclonal antibody [27] may be”
BackgroundSharma, R. K., Elpek, K. G., Yolcu, E. S., Schabowsky, R.-H., Zhao, H., Bandura‐Morgan, L., & Shirwan, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3141 · Cited by 82
“however, may be associated with severe toxicity as shown in selected settings in rodents (8, 9) and human (10).”
Anti-inflammatory T-cell shift in neuropathic pain
Luchting, B., Rachinger-Adam, B., Heyn, J., Hinske, L. C., Kreth, S., & Azad, S. C. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0225-0 · Cited by 118
“In humans, the first Treg-expanding tests were stopped because of life-threatening side effects [19].”
BackgroundResultHigh-volume Hemofiltration in the Intensive Care Unit
Rimmele, T. R., Kellum, J. A., & Warner, D. S. (2012) · Anesthesiology · doi:10.1097/aln.0b013e318256f0c0 · Cited by 85
Organs-on-chips: research and commercial perspectives
Balijepalli, A., & Sivaramakrishan, V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.009 · Cited by 90
Shum, H., Chan, K., Kwan, M., & Yan, W. (2013) · Hong Kong Medical Journal · doi:10.12809/hkmj133910 · Cited by 83
Grow, D. A., McCarrey, J. R., & Navara, C. S. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.08.013 · Cited by 95
Cyclic AMP underpins suppression by regulatory T cells
Bodor, J., Bopp, T., Vaeth, M., Klein, M., Serfling, E., Hünig, T., Becker, C., Schild, H., & Schmitt, E. (2012) · European Journal of Immunology · doi:10.1002/eji.201141578 · Cited by 90
Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28
Mirenda, V., Jarmin, S. J., David, R., Dyson, J., Scott, D., Gu, Y., Lechler, R. I., Okkenhaug, K., & Marelli‐Berg, F. M. (2006) · Blood · doi:10.1182/blood-2006-10-050724 · Cited by 90
Rapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice
Gogishvili, T., Langenhorst, D., Lühder, F., Elias, F., Elflein, K., Dennehy, K. M., Gold, R., & Hünig, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004643 · Cited by 79
“We also investigated the levels of other circulating cytokines (ILs 4, 5, 6, 10, 12; IFNc and TNF) which had contributed to the syndrome observed in the human volunteers of the TGN1412 study [20].”
BackgroundInfluentialTamaki, C., Nagayama, T., Hashiba, M., Fujiyoshi, M., Hizue, M., Kodaira, H., Nishida, M., Suzuki, K., Takashima, Y., Ogino, Y., et al. (2013) · The Journal of Toxicological Sciences · doi:10.2131/jts.38.581 · Cited by 79
Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
Waibler, Z., Sender, L. Y., Merten, C., Hartig, R., Kliche, S., Gunzer, M., Reichardt, P., Kalinke, U., & Schraven, B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001708 · Cited by 79
“These were associated with the induction of a cytokine storm, i.e. the release of high amounts of proinflammatory cytokines, most notably TNF-a and IFN-c [21].”
BackgroundInfluentialThe calm after the cytokine storm: lessons from the TGN1412 trial
St. Clair, E. W. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35382 · Cited by 79
BTB-ZF transcriptional regulator PLZF modifies chromatin to restrain inflammatory signaling programs
Sadler, A. J., Rossello, F. J., Yu, L., Deane, J. A., Yuan, X., Wang, D., Irving, A. T., Kaparakis‐Liaskos, M., Gantier, M. P., Ying, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409728112 · Cited by 81
“T innate immune system is essential to protect against infectious pathogens, although the resulting response encodes potent antimicrobial and proinflammatory agents that are inherently harmful (1, 2).”
BackgroundMethodPoirier, N., Mary, C., Dilek, N., Hervouet, J., Minault, D., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04164.x · Cited by 83
“Furthermore, the phase I clinical trial of a superagonistic anti-CD28 antibody (TGN1412) proved to be catastrophic because, unexpectedly, it provoked a rapid and massive cytokine storm that caused severe and life-threatening adverse effects (54).”
BackgroundThe Nuremberg Code subverts human health and safety by requiring animal modeling
Greek, R., Pippus, A., & Hansen, L. A. (2012) · BMC Medical Ethics · doi:10.1186/1472-6939-13-16 · Cited by 78
“Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.”
BackgroundInfluentialGilson, C. R., Milas, Z. L., Gangappa, S., Hollenbaugh, D. L., Pearson, T. C., Ford, M. L., & Larsen, C. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900339 · Cited by 82
“It should be noted that while these results help to establish the efficacy of anti-CD40 mAbs in transplantation and provide a springboard for mechanistic studies of these antibodies, mouse models are sometimes limited in their ability to predict side effects related to antibody administration in human subjects (17,70-…”
Low-affinity Fcγ receptors, autoimmunity and infection
Willcocks, L. C., Smith, K. G. C., & Clatworthy, M. R. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001161 · Cited by 87
Anti-CD40 agonist antibodies: Preclinical and clinical experience
Khalil, M., & Vonderheide, R. H. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.06.001 · Cited by 84
Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease
Goel, G., Daveson, A. J. M., Hooi, C. E., Tye–Din, J. A., Wang, S., Szymczak, E., Williams, L. J., Dzuris, J. L., Neff, K. M., Truitt, K. E., et al. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13369 · Cited by 86
Clinical relevance of the severe abnormalities of the T cell compartment in septic shock patients
Monserrat, J., de Pablo, R., Reyes, E., Díaz, D., Barcenilla, H., Zapata, M. R., de la Hera, A., Prieto, A., & Álvarez‐Mon, M. (2009) · Critical Care · doi:10.1186/cc7731 · Cited by 88
“Recently, it has been reported that the stimulation of CD28 by a monoclonal antibody in healthy volunteers is followed by severe multiple cytokinerelease syndrome [28].”
BackgroundImmune Tolerance and Transplantation
Alpdoğan, Ö., & van den Brink, M. R. M. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.10.001 · Cited by 86
T-cell co-stimulatory pathways in autoimmunity
Goronzy, J. J., & Weyand, C. M. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2414 · Cited by 89
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Jeong, S., & Park, S. (2020) · Immune Network · doi:10.4110/in.2020.20.e3 · Cited by 84
“However, in a phase I trial of the antiCD28 mAb TGN1412, non-specific CD28 signaling led to systemic inflammatory response (cytokine storm) (24).”
BackgroundLi, Q., Zhang, X., Zhang, C., Zhang, Y., Niu, M., Chen, Z., Zhang, S., He, J., Chen, W., & Zhang, X.-Z. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c05148 · Cited by 92
Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors
Gilboa, E., McNamara, J. O., & Pastor, F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2067 · Cited by 85
Clinical immunotoxicity of therapeutic proteins
Descotes, J., & Gouraud, A. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802525496 · Cited by 77
“(2008) 4(12) 1541 administered TGN1412, an anti-CD28 superagonistic mAb during a Phase I clinical trial [38] , most if not all of our current understanding of these reactions has been available for some time [39] .”
BackgroundGriessinger, C. M., Maurer, A., Kesenheimer, C., Kehlbach, R., Reischl, G., Ehrlichmann, W., Bukala, D., Harant, M., Cay, F., Brück, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418391112 · Cited by 76
“A possible advantage of the activation induced cell death is a reduced risk for overwhelming autoinflammatory reactions (18).”
BackgroundGetting specific: monoclonal antibodies in multiple sclerosis
Lutterotti, A., & Martinꝉ, R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70110-8 · Cited by 83
Cortellino, S., Raveane, A., Chiodoni, C., Delfanti, G., Pisati, F., Spagnolo, V., Visco, E., Fragale, G., Ferrante, F., Magni, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111256 · Cited by 79
Mahalmani, V., Sinha, S., Prakash, A., & Medhi, B. (2022) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_860_22 · Cited by 87
“[8] Another tragic mishap of BIA 10-2474, a FAAH inhibitor in Phase I clinical trial was a major setback to researchers.”
Findlay, L., Eastwood, D., Stebbings, R., Sharp, G., Mistry, Y., Ball, C., Hood, J., Thorpe, R., & Poole, S. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.10.013 · Cited by 74
“The rapid induction of proinflammatory cytokines, characteristic of inflammatory responses, was reported to be responsible for the adverse events and the term “cytokine storm” was coined to help explain the phenomenon (Suntharalingam et al., 2006).”
BackgroundResultSpecies selection considerations for preclinical toxicology studies for biotherapeutics
Bussiere, J. L. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.871 · Cited by 80
“A weight of evidence approach evaluating all available data may help to prevent issues such as those seen with the clinical administration of TGN1412, where six healthy male volunteers suffered from a systemic inflammatory response characterized as a ‘cytokine storm’ and became critically ill, which had not been predi…”
BackgroundRational combinations of immunotherapeutics that target discrete pathways
Spranger, S., & Gajewski, T. F. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-16 · Cited by 82
“This certainly was observed with an anti-CD28 monoclonal antibody being evaluated as a potential treatment for autoimmunity [46].”
BackgroundAfter TGN1412: Recent developments in cytokine release assays
Stebbings, R., Eastwood, D., Poole, S., & Thorpe, R. (2013) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.711783 · Cited by 73
“In contrast, TGN1412 stimulated release of >5000 pg/ml IL-2 in trial volunteer sera after 4 h (Suntharalingam et al., 2006), consistent with the greater severity of response compared to Muromonab-CD3.”
BackgroundResultHighways to hell: Mechanism-based management of cytokine storm syndromes
Canna, S., & Cron, R. Q. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.09.016 · Cited by 76
“The life-threatening responses following the administration of TGN1412, a CD28 superagonistic antibody, provided an early clue to the CSSs and shock that such costimulation can induce.(74) However, bispecific T-cell–engaging antibodies, which tether B-cell antigens to T-cell receptors, have demonstrated that CRS does…”
T Cell Ig and Mucin Domain Proteins and Immunity
Kane, L. P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902937 · Cited by 73
“Although such Abs functioned in preclinical models to preferentially expand regulatory T cells at the expense of effector T cells, they were actually quite effective at activating memory/effector T cells in humans, resulting in a potentially fatal cytokine storm (52).”
BackgroundTargeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
Peggs, K. S., Segal, N. H., & Allison, J. P. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.023 · Cited by 79
Tao, W., Mao, X., Davide, J. P., Ng, B., Cai, M., Burke, P. A., Sachs, A. B., & Sepp-Lorenzino, L. (2011) · Molecular Therapy · doi:10.1038/mt.2010.282 · Cited by 73
Vasaturo, A., Blasio, S. D., Peeters, D. G. A., de Koning, C. C. H., de Vries, I. J. M., Figdor, C. G., & Hato, S. V. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00417 · Cited by 88
“This antibody led to an unexpected release of cytokines (cytokine storm) in the volunteers, causing severe toxicities (82).”
BackgroundAre BiTEs the “missing link” in cancer therapy?
Suryadevara, C. M., Gedeon, P. C., Sanchez-Perez, L. A., Verla, T. G., Alvarez-Breckenridge, C. A., Choi, B. D., Fecci, P. E., & Sampson, J. H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008339 · Cited by 80
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Galbraith, G. M. P. (2007) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70546-x · Cited by 72
CD28 co-stimulation: novel insights and applications in cancer immunotherapy
Lotze, M. T., Olejniczak, S. H., & Skokos, D. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01061-1 · Cited by 92
Programmed Death‐1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy
Dömling, A. S. S., & Holak, T. A. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307906 · Cited by 83
Leavenworth, J. W., Schellack, C., Kim, H.-J., Lu, L., Spee, P., & Cantor, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914732107 · Cited by 71
A rationale for using steroids in the treatment of severe cases of H5N1 avian influenza
Carter, M. J. (2007) · Journal of Medical Microbiology · doi:10.1099/jmm.0.47124-0 · Cited by 71
“A demonstration of the power of acute hypercytokinaemia was recently illustrated in a clinical phase 1 trial of the anti-CD28 mAb TGN1412 in six young healthy males (Suntharalingam et al., 2006).”
BackgroundWhat is a Humanized Mouse? Remaking the Species and Spaces of Translational Medicine
Davies, G. F. (2012) · Body & Society · doi:10.1177/1357034x12446378 · Cited by 81
“The most recent was the catastrophic failure of pre-clinical safety trials at Northwick Park, in north London, in 2006 (Suntharalingam et al., 2006).”
Background
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.